Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms

Wojciech Jurczak; Alicja Hubalewska-Dydejczyk; Agnieszka Giza; Anna Sowa-Staszczak; Bohdan Huszno; Aleksander B. Skotnicki

Vol 10, No 2 (2007)

Review paper

Submitted: 2012-01-23

Published online: 2007-05-23

View PDF

Download PDF file

Get Citation

Radioimmunotherapy for lymphoma - analysis of clinical trials and treatment algorithms

Wojciech Jurczak, Alicja Hubalewska-Dydejczyk, Agnieszka Giza, Anna Sowa-Staszczak, Bohdan Huszno, Aleksander B. Skotnicki

Nucl. Med. Rev 2007;10(2):110-115.

Vol 10, No 2 (2007)

Reviews

Submitted: 2012-01-23

Published online: 2007-05-23

Abstract

Ibritumomab, an ⁹⁰Yttrium (⁹⁰Y) labelled radioimmunoconjugate, is registered in Europe to treat follicular lymphomas. Its mode of action combines the selectivity of monoclonal antibodies with the efficiency of radiotherapy, making it a unique and useful therapeutic agent. This paper is for haemato-oncologists with a decent practice in lymphoma therapy, who have not yet used ibritumomab themselves. It summarizes clinical trials with radioimmunotherapy, indicating clinical situations where it may be specifically useful.